Featured Research

from universities, journals, and other organizations

New method for early detection of colon cancer

Date:
September 4, 2013
Source:
American Association for Cancer Research (AACR)
Summary:
A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a new study.

A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

"Tumor cells are released into stool from the surface of precancers and early-stage colon cancers, but detecting a cancer-initiating genetic mutation among a large quantity of normal DNA from a patient's stool is like looking for a needle in a haystack," said Bettina Scholtka, Ph.D., assistant professor in the Department of Nutritional Toxicology at the University of Potsdam in Nuthetal, Germany. "By combining for the first time locked nucleic acid-based, wild-type blocking polymerase chain reaction and high-resolution melting, we were able to achieve the desired sensitivity. The extremely high sensitivity of this technique allows us to find very low amounts of different types of the cancer-initiating mutations in patients' stool samples.

"Colon precancer cells carrying these genetic variations are routinely shed in stool samples, but these cells can be detected in blood only after the cancer has advanced, so stool is better than blood if we are to catch these cancers at a very early stage," she added.

About 60 percent and 40 percent of patients with colorectal cancer have genetic variations in the genes APC and KRAS, respectively. Because these variations are also present in precancers, methods for spotting them can help detect colon cancers early. The new method described in this study can detect a single cancer-specific gene variation among 10,000 times the amount of normal DNA, and is up to 5,000-fold more sensitive than other noninvasive screening methods.

A multicenter study is needed to validate the sensitivity and specificity of this new method in comparison with standard screening methods like colonoscopy, according to Scholtka.

Scholtka and colleagues used 80 human colon tissue samples representing cancers and precancers to detect genetic variations using a combination of two techniques: The first technique -- locked nucleic acid (LNA)-based, wild-type blocking (WTB) polymerase chain reaction -- suppressed normal DNA present in large quantities in the sample; and the second technique -- high-resolution melting (HRM) -- enhanced the detection of genetic variations.

The researchers were able to detect APC variations in 41 of the 80 samples. They were also able to detect previously unknown variations in APC. In contrast, the routinely used technique called direct sequencing could detect variations only in 28 samples.

They then analyzed 22 stool samples from patients whose colon tissues had APC variations, and nine stool samples from patients whose colon tissues did not have APC variations, as controls. They were able to detect APC variations in 21 out of 22 samples.

The researchers also detected variations in the KRAS gene using 20 human colon tissue samples to demonstrate that the WTB-HRM method can be used to detect variations in genes other than APC.

"By using our technique for examining a selection of genes that become mutated during the process of colon cancer formation, it is possible to detect the very first stage of colon cancer and even precancers in a stool sample," said Scholtka. "It will be possible to prevent cancer in many cases by removing the precancerous lesions after early detection."


Story Source:

The above story is based on materials provided by American Association for Cancer Research (AACR). Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Gerecke, C. Mascher, U. Gottschalk, B. Kleuser, B. Scholtka. Ultrasensitive Detection of Unknown Colon Cancer-Initiating Mutations Using the Example of the Adenomatous Polyposis Coli Gene. Cancer Prevention Research, 2013; 6 (9): 898 DOI: 10.1158/1940-6207.CAPR-13-0145

Cite This Page:

American Association for Cancer Research (AACR). "New method for early detection of colon cancer." ScienceDaily. ScienceDaily, 4 September 2013. <www.sciencedaily.com/releases/2013/09/130904092459.htm>.
American Association for Cancer Research (AACR). (2013, September 4). New method for early detection of colon cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/09/130904092459.htm
American Association for Cancer Research (AACR). "New method for early detection of colon cancer." ScienceDaily. www.sciencedaily.com/releases/2013/09/130904092459.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins